|
 The drug developer's stock was down about 19 percent in light
premarket trading on Thursday.
The treatment, sapacitabine, was tested on patients aged 70 years or
more who are not candidates for chemotherapy or have refused it,
Cyclacel said.
An improvement in remission rates - a secondary goal - was there for
patients who had discontinued therapy at the time of analysis, the
company added.
Cyclacel said it was going to reevaluate its continued investment in
sapacitabine for blood cancer.
(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Savio
D'Souza and Shounak Dasgupta)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
